Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback